Europe needs 'proper' cannabidiol regulations for foods and supplements, says association

Europe needs 'proper' cannabidiol regulations for foods and supplements, says association

The European Industrial Hemp Association (EIHA) says there is an “urgent need for proper legislation” in a position paper asking for Europe to recognise cannabidiol (CBD) and hemp as safe ingredients in food and cosmetics – not just medicines.

Some member states, including Britain, currently only recognise CBD as a medicinal product, rather than an over-the-counter (OTC) food supplement.

In the position paper the organisation says “it is just and reasonable that CBD is not covered by the national narcotic acts or drug regulations of the 27 EU Member States (from 28 with the exception of Slovakia) and that CBD is not restricted by any EU legislation”.

The EIHA has proposed a three-tier regulation system: high doses (200 mg/day or more) of CBD should be regulated as a medicinal product; medium doses of CBD (20-200 mg/day) should be considered an OTC product or a food supplement; and low CBD doses (20 mg/day or less) should be allowed in food products with no restrictions.

The organisation acknowledges that different regulations will have to apply to CBD containing hemp extracts, compared to pure CBD, as it could contain tetrahydrocannabinol (THC – the psychoactive cannabidiol in marijuana) as well.

Medium doses of CBD should be available to buy as herbal medicines or food supplements, without prescription, in chemists, pharmacies or health stores EIHA says.

EIHA also say they are strictly opposed to attempts made by pharmaceutical companies to  make CBD a prescription-only drug, saying “this only serves the interest of a few companies while damaging the young CBD industry”.

The Medicines and Health Regulatory Agency (MHRA) in the UK released their opinion that CBD products are medicines last year.

A spokesperson said: “MHRA is not currently aware of any safety issues related to consumption of CBD but it should be noted that the assessment of whether a product is classified as a ‘medicinal product’ is carried out in accordance with the definition of a medicinal product and is not based on whether the product is a risk to consumers. Once a valid application is made the product will be assessed in terms of its safety quality and efficacy in the medical claims made”.

The EIHA has said, however, that there is no need for such strict regulations over CBD products, as the ingredient has no side effects and is non-psychotropic.

Tony Reeves, board advisor for EIHA and managing director of HempCo Europe, said: "The document we have distributed provides a sensible, considered and workable framework for the regulation of CBD's across Europe and is extremely well supported by a sound science-based rationale. In my experience, both the regulators and responsible producers share a common goal in that they all wish to protect the consumer without restricting access to what is a natural, safe and beneficial food supplement. I strongly believe that this position paper provides exactly the framework to achieve these goals".

Related News

Canadian firm to launch cannabidiol nutraceutical in UK

Canadian firm to launch cannabidiol nutraceutical in UK

Cannabinoid nutraceuticals set for European take off?

Cannabinoid nutraceuticals set for European take off?

Hemp gummy aims for slice of €188m cannabis extract market

Hemp gummy aims for slice of €188m cannabis extract market

EU to promote plant sustainability

Cannabis medicines could hit UK next year

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.